Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma

Judy Ahrar; Sanjay Gupta; Joe Ensor; Kamran Ahrar; David C. Madoff; Michael J. Wallace; Ravi Murthy; Alda Tam; Patrick Hwu; Agop Y. Bedikian

doi:10.3109/07357907.2010.535052

Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma

Judy Ahrar, Sanjay Gupta, Joe Ensor, Kamran Ahrar, David C. Madoff, Michael J. Wallace, Ravi Murthy, Alda Tam, Patrick Hwu, Agop Y. Bedikian

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9) or disease stabilization (47.2) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p .034).

Original language	English (US)
Pages (from-to)	49-55
Number of pages	7
Journal	Cancer Investigation
Volume	29
Issue number	1
DOIs	https://doi.org/10.3109/07357907.2010.535052
State	Published - Jan 2011

Keywords

Cutaneous melanoma
Hepatic artery chemoembolization
Liver metastases

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3109/07357907.2010.535052

Cite this

@article{cb54ef09a79b417ca2eebef5670dedc0,

title = "Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma",

abstract = "We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9) or disease stabilization (47.2) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p .034).",

keywords = "Cutaneous melanoma, Hepatic artery chemoembolization, Liver metastases",

author = "Judy Ahrar and Sanjay Gupta and Joe Ensor and Kamran Ahrar and Madoff, {David C.} and Wallace, {Michael J.} and Ravi Murthy and Alda Tam and Patrick Hwu and Bedikian, {Agop Y.}",

year = "2011",

month = jan,

doi = "10.3109/07357907.2010.535052",

language = "English (US)",

volume = "29",

pages = "49--55",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma

AU - Ahrar, Judy

AU - Gupta, Sanjay

AU - Ensor, Joe

AU - Ahrar, Kamran

AU - Madoff, David C.

AU - Wallace, Michael J.

AU - Murthy, Ravi

AU - Tam, Alda

AU - Hwu, Patrick

AU - Bedikian, Agop Y.

PY - 2011/1

Y1 - 2011/1

N2 - We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9) or disease stabilization (47.2) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p .034).

AB - We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9) or disease stabilization (47.2) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p .034).

KW - Cutaneous melanoma

KW - Hepatic artery chemoembolization

KW - Liver metastases

UR - http://www.scopus.com/inward/record.url?scp=78650423886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650423886&partnerID=8YFLogxK

U2 - 10.3109/07357907.2010.535052

DO - 10.3109/07357907.2010.535052

M3 - Article

C2 - 21166498

AN - SCOPUS:78650423886

SN - 0735-7907

VL - 29

SP - 49

EP - 55

JO - Cancer Investigation

JF - Cancer Investigation

IS - 1

ER -

Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this